Showing 15 posts of 18 posts found.


Grünenthal buys European rights to AstraZeneca’s Crestor for a potential $350m

December 1, 2020
Manufacturing and Production, Sales and Marketing AstraZeneca, Crestor, Grunenthal

Grünenthal has picked up AstraZeneca’s statin therapy Crestor (rosuvastatin), currently approved in dyslipidaemia and hypercholesterolaemia treatment, in a deal worth …


AstraZeneca loses legal bid to block Crestor generics

July 20, 2016
Research and Development, Sales and Marketing AstraZeneca, Crestor, FDA, generics, legal

A US district court judge has refused AstraZeneca’s request for a temporary restraining order blocking the approval of generic versions …


AstraZeneca files suit to block FDA from approving copies of cholesterol drug Crestor

July 11, 2016
Sales and Marketing AstraZeneca, Crestor, US FDA, patent, regulation

Anglo-Swedish drug firm AstraZeneca (LSE: AZN) has filed a temporary restraining order to prevent the US Food and Drug Administration from …


Allergan launches Crestor generic in the US

May 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales

Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …


AZ warns of patent losses as revenues fall

February 4, 2016
Medical Communications, Sales and Marketing AstraZeneca, Crestor, Zurampic

AstraZeneca announced full-year revenues down 7% to $24.7 billion, and Q4 sales down 5% to $6.4 billion, as the London-based …

Astrazeneca image

More changes at the top as AstraZeneca profits slip

November 1, 2013
Sales and Marketing AstraZeneca, Crestor, Q3, profits

AstraZeneca’s third quarter revenues and profits fell below analysts’ expectations yesterday, but mitigated the news with the appointment of a …

crestor image

AstraZeneca settles Crestor case

March 26, 2013
Sales and Marketing AstraZeneca, Crestor, Watson

AstraZeneca has settled a long-running legal battle over one of its biggest brands, Crestor, whose patent expires in 2016. The …

Shionogi opens UK office

July 9, 2012
Research and Development, Sales and Marketing Crestor, Japan, Osaka, Shionogi, cholesterol

Japanese pharma firm Shionogi & Co has opened a new office in London and pledged to expand into Europe. Osaka-based …

AstraZeneca's Crestor (rosuvastatin)

Crestor fails head-to-head test against Lipitor

September 2, 2011
Sales and Marketing Crestor, Lipitor

AstraZeneca’s cholesterol drug Crestor has failed to show it can stop artery disease better than Pfizer’s Lipitor. The new study …

Caution raised on statins in healthy people

January 20, 2011
Sales and Marketing Cochrane, Crestor, Lipitor, statin, statin prescribing

Researchers have warned of a lack of evidence to support prescribing statins in patients at low risk of developing heart …


Patent expiries bite into AstraZeneca revenues

October 29, 2010
Sales and Marketing AstraZeneca, Crestor, Q3, Seroquel

Generic competition and a major drop off in pandemic influenza products saw AstraZeneca’s revenue fall for the third quarter. Revenue …

Watson submits Crestor copycat

October 28, 2010
Sales and Marketing AstraZeneca, Crestor, Watson, generic, patent

 Watson Pharmaceuticals is seeking to launch a generic version of  AstraZeneca cholesterol blockbuster Crestor, exploiting weaknesses in its patent. The …

Crestor victory lifts AstraZeneca

July 1, 2010
Sales and Marketing AstraZeneca, Crestor

AstraZeneca has defeated a challenge to the US patent on its blockbuster cholesterol drug Crestor. A US District Judge in …


Crestor gains prevention licence in Europe

April 27, 2010
Sales and Marketing AstraZeneca, Crestor, statin

AstraZeneca’s statin treatment Crestor has been approved in the European Union for the prevention of major cardiovascular events in patients …

Latest content